Psychedelics and Autism Therapy: A Review of Current Research and Future Directions
Current Issues in Molecular Biology · 18.04.2026 · 48 (4) · 417
DOI: 10.3390/cimb48040417 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 18.04.2026. Verfasst von Christopher S Gondi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Internal Medicine, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA. Die Arbeit nennt 259 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Autism Spectrum Disorder (ASD) is a lifelong condition marked by challenges in social communication and repetitive behaviors. Current treatments, primarily behavioral therapies, often fail to address the core symptoms. Recent research has explored the potential of psychedelics, such as LSD, psilocybin, and MDMA, as a new therapeutic approach. While these substances primarily modulate the serotonin 5-HT2A receptor, their therapeutic effects also involve interactions with other serotonergic, dopaminergic, and glutamatergic pathways, collectively promoting neuroplasticity—the brain’s ability to change and adapt. The specific receptors’ activation leads to structural and functional changes in the brain that can enhance social behavior and emotional regulation. Studies show that psychedelics may reduce symptoms of conditions like treatment-resistant depression and PTSD, highlighting their therapeutic potential. For ASD specifically, psychedelics may improve psychological flexibility, reduce distress, and enhance social interaction. While promising, the use of these substances requires careful consideration. Psychedelics can induce intense experiences and altered states of consciousness, necessitating strict monitoring and support during therapy. Ethical guidelines, including informed consent, are crucial, especially for vulnerable populations. In conclusion, psychedelics hold significant promise for treating ASD and other psychiatric disorders by promoting neuroplasticity and modulating complex signaling pathways. Continued research and clinical trials, conducted with strong ethical oversight, are essential to realizing their full therapeutic potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of Internal Medicine, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.
- Departments of Surgery, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.
- Departments of Health Science Education and Pathology, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.
- Health Care Engineering Systems Center, The Grainger College of Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
- Departments of Pediatrics, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.
- School of Communication and Media, University of Illinois Springfield, Springfield, IL 62703, USA.
ORCID-Profile: Christopher S Gondi, Manu Gnanamony, Lusine Demirkhanyan
Zitieren
APA
Gondi, C. S., Gnanamony, M., Gondi, T. P., Nersesyan, L., & Demirkhanyan, L. (2026). Psychedelics and Autism Therapy: A Review of Current Research and Future Directions. Current Issues in Molecular Biology, 48(4), 417. https://doi.org/10.3390/cimb48040417
Vancouver
Gondi CS, Gnanamony M, Gondi TP, Nersesyan L, Demirkhanyan L. Psychedelics and Autism Therapy: A Review of Current Research and Future Directions. Current Issues in Molecular Biology. 2026;48(4):417. doi:10.3390/cimb48040417
BibTeX
@article{Gondi2026,
author = {Gondi, Christopher S and Gnanamony, Manu and Gondi, Tarun P and Nersesyan, Lilyt and Demirkhanyan, Lusine},
title = {Psychedelics and Autism Therapy: A Review of Current Research and Future Directions},
journal = {Current Issues in Molecular Biology},
year = {2026},
volume = {48},
number = {4},
pages = {417},
doi = {10.3390/cimb48040417}
}
EUVIMED